Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma

M Burotto, SA Ali… - Expert Opinion on Drug …, 2015 - Taylor & Francis
Introduction: The past decade has seen the development and widespread use of tyrosine
kinase inhibitors (TKIs) targeting a mutated EGFR (mEGFR) for the treatment of metastatic …

Mapping bone marrow response in the vertebral column by positron emission tomography following radiotherapy and erlotinib therapy of lung cancer

A Abravan, HA Eide, AM Løndalen, Å Helland… - Molecular Imaging and …, 2019 - Springer
Purpose To map functional bone marrow (BM) by 2-deoxy-2-[18 F] fluoro-d-glucose ([18 F]
FDG) positron emission tomography (PET) in the vertebral column of lung cancer patients …

Rapid evaluation of tyrosine kinase activity of membrane-integrated human epidermal growth factor receptor using the yeast Gγ recruitment system

N Fukuda, S Honda - ACS Synthetic Biology, 2015 - ACS Publications
Epidermal growth factor receptor (EGFR) is a member of the receptor tyrosine kinase family
and plays key roles in the regulation of fundamental cellular processes, including cell …

Development and validation of a UPLC–MS/MS assay for the quantification of simotinib in human plasma

N Li, X Han, P Du, Y Song, X Hu, S Yang… - Analytical and bioanalytical …, 2014 - Springer
Simotinib is a novel oral small-molecule tyrosine kinase inhibitor that has demonstrated
equal or superior antineoplastic activities to erlotinib in preclinical studies. In support of a …

Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies

S Das, B Bhattacharya, B Das, B Sinha… - Indian Journal of …, 2021 - Springer
Cancer is one of the dominant causes of death worldwide while lifelong prognosis is still
inauspicious. The maturation of the cancer is seen as a process of transformation of a …

Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!

S Stintzing, HJ Lenz - Expert opinion on pharmacotherapy, 2013 - Taylor & Francis
Introduction: Increased understanding in intracellular signaling pathways leading to
carcinogenesis, proliferation, migration, invasion, angiogenesis, and anti-apoptosis of …

[HTML][HTML] International biobanking for lung cancer and COPD as the future resource for clinical protein research

TE Fehniger, Á Végvári, M Rezeli, B Döme, J Tímár… - EuPA Open …, 2013 - Elsevier
Characterized tissue with pathological grading and blood samples as well as other biofluids
forms the basis for all biobanks as a resource in modern life science. Biobanks are accessed …

[HTML][HTML] Gefitinib in non-small-cell lung cancer—an old lesson new re-visited

WCM Dempke - Translational Lung Cancer Research, 2013 - ncbi.nlm.nih.gov
Non-small cell lung cancer (NSCLC) accounts for approximately 80-85% of all cases of lung
cancer, and it is the most common cause of death in men and second only to breast cancer …

[HTML][HTML] Biopsy testing in an inoperable, non-small cell lung cancer population—a retrospective, real-life study in Sweden

H Koyi, L Johansson, J From, S Nyrén - Journal of thoracic disease, 2015 - ncbi.nlm.nih.gov
Background Correct diagnosis and staging are required for optimal treatment choice in lung
cancer patients. This retrospective, patient medical records study investigated the clinical …

[HTML][HTML] Los medicamentos de origen biotecnológico, el futuro comienza ahora

JE Machado-Alba - Anales de la Real Academia Nacional de …, 2014 - anales.ranf.com
Los medicamentos de origen biotecnol—gico pueden ser anticuerpos monoclonales o
molŽculas peque–as dise–adas para actuar sobre blancos terapŽuticos definidos. Se hizo …